Type 2 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People between 18 and 65 years old
- People with a body mass index (BMI) of 35 kg/m² (a measure of body weight relative to height)
- People who have been diagnosed with Type 2 diabetes, based on Diabetes Canada's diagnostic criteria
- People who have been diagnosed without Type 2 diabetes, based on Diabetes Canada's diagnostic criteria
- Women who have a negative blood pregnancy test at the time of screening
Who may not be able to join:
- People currently taking oral contraceptive (birth control) pills
- People taking certain medications including fibrates, thiazolidinediones, insulin, or beta-blockers — drugs that affect the body's metabolism and cannot be safely paused or that have long-lasting effects
- People with serious heart or blood vessel disease, liver failure, kidney failure, or other medical conditions that are not well controlled
- People for whom surgery would not be safe, or for whom it would not be safe to temporarily stop their current medications for diabetes, cholesterol, or blood pressure
- People who smoke, or who drink more than 2 alcoholic beverages per day
- People for whom an MRI scan would not be safe (confirm with trial site for specific reasons)
- People with a DiaRem score higher than 8, which is a scoring tool indicating a low likelihood of Type 2 diabetes going into remission (confirm with trial site)
- People who took part in a research study involving radiation exposure within the two years before this study begins
- Women who are pregnant or breastfeeding
- People who weigh more than 200 kg, due to the weight limits of the scanning equipment used in the study
- People with an egg allergy
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: André Carpentier, MD, Université de Sherbrooke
Phone: 1-819-346-1110
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in white adipose tissue dietary fatty acid (DFA) trapping and partitioning; Change in lean organ (liver, heart and muscle) DFA uptake and partitioning; Change in liver non-esterified fatty acid (NEFA) uptake, oxidation, esterification and secretion into very low-density lipoprotein (VLDL).; Change in Endogenous Glucose production and meal glucose systemic flux; Change in cardiac non-esterified fatty acid (NEFA) uptake, oxidation and esterification
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.